![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Psychiatric diagnostic profiles, drug and personal histories, and social support measures were obtained for a clinic sample of abusers of pentazocine when the drug was withdrawn and re-released by the manufacturer compounded with the opiate antagonist naloxone. Nearly 50% of the sample (N = 99) reported using the new drug during the following 6 to 9 months, despite its reduced abuse potential. Reinterviews revealed that claimed use of pentazocine dropped to half.